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S186 Oral PresentationsHowever, malignant disease remained a predictor for lower OS.
(HR53.38(1.37 -7.3 at 95% CI, p5 0.007). In multivariate analy-
sis of OS modeling, comparing mean values acquired only between
day 0 to Day 365, more accelerated thymic recovery in the first year
(.9% of circulating T cells with a RTE phenotype [CD62L+/
CD45RA+]), was the only immune parameter that was associated
with a reduced risk of death at any time point, HR 0.20 (0.07-
0.60, 95%CI), p5 0.004.
Conclusion: Even among children with relatively better preserved
thymus compared to adults, those with more rapid thymic recovery
leading to more robust rise in RTE will have superior clinical out-
come. These findings should spur further research aiming to en-
hance recovery of the central, thymic derived pathway of T cell
generation.SOLID TUMORS
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CMV-SPECIFIC HER2-REDIRECTED T CELLS FOR THE ADOPTIVE IMMU-
NOTHERAPY OF GLIOBLASTOMA
Ahmed, N.1, Salsman, V.S.1, Kew, Y.2, Shaffer, D.1, Powell, S.Z.2,
Grossman, R.G.2, Bollard, C.M.1,2, Heslop, H.E.1,2, Gottschalk, S.1 1Cen-
ter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;
2The Methodist Hospital Research Institute, Houston, Texas
Background:We demonstrated that T cells fromGBMpatients en-
gineered to express a HER2-specific chimeric antigen receptor
(CAR) kill autologous HER2 +GBM cells ex vivo, including the
CD133 +GBM stem cell population. In vivo, the adoptive transfer
of HER2-specific T cells resulted in regression of established
GBM in the brain of mice, yet tumors recurred in a number of
treated animals. This limitation in T-cell efficacy is most likely
due to a) limited T-cell persistence in vivo and/or b) tumor antigen
loss variants in treated tumors. Since the majority of GBMs are pos-
itive for CMVpp65 we expressed HER2.CARs in CMV-specific cy-
totoxic T cells (CTLs) to a) enhance their persistence in vivo
following native T-cell receptor (abTCR) engagement with CMV-
antigens and b) improve their antitumor activity by simultaneously
targeting CMV and HER2.
Methods: To study the feasibility of generating CMV CTLs from
GBMpatients, we determined the precursor frequency of CMV-spe-
cific T cells in 12 patients using IFN-g ELIspot assays. To generate
CMV CTL ex vivo, peripheral blood mononuclear cells were trans-
duced with an adenovirus vector; encoding the immunodominant
CMV-pp65 antigen (Ad5f35pp65) then stimulated with autologous
EBV transformed Ad5f35pp65-transduced irradiated lymphoblastic
cell lines (EBV-LCL). CTLs were then transduced with a retroviral
vector encoding a HER2.CAR (FRP5.CD28.z). We detected
the expression of the CAR transgene using flowcytometry. To con-
comitantly identify the CMV-specific T cell population we used
pentamer analysis for CMVpp65. We performed 51Cr-release
assays to characterize the functionality of HER2.CAR CMV.CTLs
ex vivo.
Results:CMV-specific T cells were readily detectable in the blood
of GBM patients as judged by IFN-g secretion after stimulation
with CMVpp65 PepMixes. We were able to generate CTLs
that are specific for CMV through their endogenous ab TCR
and specific for HER2 through the CAR. Approximately 50% of
CMVpp65-specific CTLs expressed HER2.CARs on the cell sur-
face. CMV-specific CTLs expressing the HER2-specific CAR rec-
ognized and killed the HER2-positive GBM cell line (U373) as well
as autologous OKT3-blasted T cells pulsed with CMVpp65 Pep-
Mixes in a standard 4 hour 51Cr-release assays. Neither the
HER2 –ve cell lines nor autologous OKT3-blasted T cells were
killed.
Conclusion: Our data demonstrates the feasibility of generating
CAR expressing CMVpp65-specific CTLs that are functional
against HER2 and CMV expressed in GBM.84
OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS
STEM CELL TRANSPLANTATION (ASCT) IN COMPARISON TO CONVEN-
TIONAL CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH HIGH RISK
EWING’S FAMILY TUMORS
Jodele, S.1, Davies, S.M.1, Wagner, L.M.2, Mehta, P.A.1, Bleesing, J.J.1,
Filipovich, A.H.1, Marsh, R.A.1, Jordan, M.B.1, Kim, M.3,
Perentesis, J.P.2 1Cincinnati Childrens Hospital Medical Center
(CCHMC), OH; 2Cincinnati Childrens Hospital Medical Center, OH;
3Cincinnati Childrens Hospital Medical Center, OH
Pediatric patients with high risk Ewing’s family tumors (hrEFT),
relapsed or metastatic at diagnosis, have very poor outcome
with conventional chemotherapy. A steep dose-response curve to
alkylating agents suggests myeloablative chemotherapy as a poten-
tial therapeutic modality, but controversy persists, warranting
additional investigation. We retrospectively reviewed hrEFT
patients treated with conventional therapy (CHEMO) in compari-
son to high dose alkylator-based chemotherapy and autologous
stem cell transplantation (ASCT) treated at a single center.
Thirty-six patients were assigned into 4 groups based on disease
features and therapy received: REL/CHEMO (n5 12), REL/
ASCT (n5 5), MET/CHEMO (n5 14), MET/ASCT (n5 5).
Kaplan-Meier estimator was used to compare event free survival
(EFS) and overall survival (OS). Seven of 10 ASCT patients
received busulfan, melphalan, thiotepa and 3 of 10 received mel-
phalan, carboplatin and etoposide prior to autologous peripheral
blood stem cell rescue. Both regimens included the chemoprotec-
tant amifostine. Patients had complete response (CR), very
good partial response (VGPR) or partial disease response (PR) at
the time of ASCT. REL/CHEMO patients received a variety of
salvage non-high dose chemotherapies. EFS at 1 and 3 years
from 1st relapse were 100% and 53% in REL/ASCT group in com-
parison to 25% and 8% respectively in REL/CHEMO group
(p5 0.0007). OS at 1 and 3 years from diagnosis were 100% and
80% for REL/ASCT group and 92% and 42% respectively in
REL/CHEMO group (p5 0.013). ASCT-related toxicities were
febrile neutropenia and grade 3 mucositis (n5 10), adrenal insuffi-
ciency (n5 4), bacteriemia (n5 1), and herpes zoster reactivation
(n5 3). We did not observe any veno-occlusive disease of liver
(VOD) or graft failure. There were no regimen-related mortalities.
Four of 5 patients are surviving in the REL/ASCT group, and all
are currently disease-free (one after a further relapse) with a median
time from 1st relapse of 3.3 years (range 1.7-8.9). In comparison,
none of the 12 children with relapsed disease treated with chemo-
therapy alone are surviving, with median time from relapse to death
of 1 year (range 0.1-4.8). In patients with metastatic disease at di-
agnosis, the 1-year OS was 75% in MET/ASCT group, and 64%
respectively in MET/CHEMO group (p5 0.79). Our data suggest
ASCT is tolerable and should be considered as therapeutic option
for relapsed patients. Randomized studies are required to support
these observations.STEM CELL BIOLOGY
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SYSTEMIC ADMINISTRATION OF PLEIOTROPHIN INDUCES HEMATOPOI-
ETIC STEM CELL (HSC) REGENERATION IN VIVO
Himburg, H.A., Daher, P., Meadows, S.K., Russell, J.L., Doan, P.,
Chao, N.J., Chute, J.P. Duke University, Durham, NC
The elucidation of bone marrow microenvironmental signals
which promote HSC regeneration in vivo would have important
implications for the treatment of patients undergoing radiation
therapy, chemotherapy and stem cell transplantation. We recently
reported that pleiotrophin, a soluble heparin-binding growth fac-
tor, induced a 10-fold expansion of long-term repopulating HSCs
in culture (Himburg et al. Blood, Nov 2008; 112: 78). Based on
this observation, we hypothesized that PTN might also be a regen-
erative growth factor for HSCs. Here we tested the effect of sys-
temic administration of PTN to mice to determine if PTN could
promote HSC regeneration in vivo following total body irradiation
(TBI). C57Bl6 mice were irradiated with 700 cGy followed by
Oral Presentations S187intraperitoneal administration of 2 mg PTN or saline  7 days, fol-
lowed by analysis of BM stem and progenitor cell content. Saline-
treated mice demonstrated a significant reduction in total BM cells,
BM c-kit+sca-1+lin- (KSL) cells, colony forming cells (CFCs) and
long term culture-initiating cells (LTC-ICs) compared to non-irra-
diated mice. Irradiated, PTN-treated mice demonstrated a 2.3-fold
increase in total BM cells (p5 0.03), a 5.6-fold increase in BM KSL
stem/progenitor cells (p5 0.04), a 2.9-fold increase in BM CFCs
(p5 0.004) and an 11-fold increase in LTC-ICs (p5 0.03) com-
pared to irradiated, saline-treated mice. Moreover, competitive
repopulating assays demonstrated that BM from irradiated,
PTN-treated mice contained 5-fold increased competitive repopu-
lating units (CRUs) compared to irradiated, saline-treated mice
(p5 0.04). Taken together, these data demonstrate that the admin-
istration of PTN induces BM HSC and progenitor cell regenera-
tion in vivo following injury. To determine whether PTN acted
directly on BM HSCs to induce their proliferation and expansion
in vivo, mice ingested BrDU  7 days and compared BrDU incor-
poration in BM KSL cells in saline-treated versus PTN-treated
mice. PTN-treated mice demonstrated a significant increase in
BrDU+ BM KSL cells compared to saline-treated controls
(p5 0.04). PTN is a novel, secreted growth factor for BM HSCs
and induces their regeneration in vivo while preserving their repo-
pulating capacity. PTN has therapeutic potential as a growth factor
to accelerate hematopoietic reconstitution in vivo in patients un-
dergoing myelosuppressive radiotherapy or chemotherapy.86
THE ROLE OF SALL4 IN EMBRYONIC STEM CELL PLURIPOTENCY
Rao, S.1,2, Roumiantsev, S.2, McDonald, L.1, Orkin, S.H.1,2,3,4 1Dana
Farber Cancer Institute, Boston, MA; 2Children’s Hospital, Boston, MA;
3Harvard Stem Cell Institute, Boston, MA; 4Howard Hughes Medical In-
stitute, Boston, MA
Murine embryonic stem cells (mESCs) can grow indefinitely
in vitro, and yet retain the potential to differentiate into all three
primitive germ layers. They hold significant promise within the
field of regenerative medicine, particularly through the production
of patient specific induced pluripotent cells (iPS), which mimic the
properties of embryonic stem cells. The ability of mESCs to main-
tain their pluripotency is regulated by a number of transcription
factors, including Sall4, the causative gene in Duane-Radial Ray
syndrome (DRSS), consisting of radial, cardiac, and eye abnormal-
ities. Sall4 is critical for maintaining mESCs in a pluripotent state,
and interestingly exists as two isoforms (Sall4a, the long isoform
and Sall4b, the short isoform); Sall4b has been implicated as an on-
cogene in acute myelogenous leukemia (AML). Using genome
wide location anaylsis, we have been able to show that both iso-
forms of Sall4 exist in mESCs and bind to overlapping but not
identical target genes. In fact, Sall4b (the short isoform) binds to
most pluripotency targets, whereas Sall4a binds predominantly to
differentiation genes. Using RNAi technology to generate mESCs
containing only one of the two isoforms we demonstrate that
Sall4b but not Sall4a is required for maintaining mESCs in a plu-
ripotent state. Lastly, proteomics reveals that Sall4a and Sall4b may
have different protein:protein interaction partners which affects
their ability to regulate pluripotency targets. Taken together, these
data indicate that differences in splice variants at a single locus can
play key roles in regulating the pluripotent states. Further studies
need to be performed to understand how these differences may
translate into the unique roles these splice isoforms play in human
diseases.87
DNA TRANSFER FROM DONOR TO HOST CELLS AS A MECHANISM FOR EP-
ITHELIAL CHIMERISM AND GENOMIC ALTERATIONS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Spyridonidis, A.1, Waterhouse, M.2, Themeli, M.1, Bertz, H.2,
Petrikkos, L.2, Lagadinou, E.1, Zoumbos, N.1, Finke, J.2 1Patras Univer-sity Medical School, Patras, Achaia, Greece; 2Albert Ludwigs University of
Freiburg, Frieburg, Germany
Research in the field of allogeneic hematopoietic cell transplan-
tation (allo-HCT) revealed hidden consequences of the co-exis-
tence of two genetically distinct populations in the transplant
recipient. First, epithelial cells with donor-derived genotype
emerge and second, epithelial tissues of the host acquire genomic
alterations. We asked whether horizontal transfer of donor-DNA
to host epithelium is operating in (and linking) both phenomena.
176 buccal samples were obtained from 71 allo-transplanted pa-
tients and analyzed with microsatellite markers for the presence
of donor-DNA and microsatellite instability. The presence of
graft-derived hematopoietic cells in the samples was excluded by
immunocytochemistry. The results were associated with clinical
data. Genomic instability induction and DNA transfer in epithelial
cells by allogeneic lymphocytes was assessed in vitro. We found
a high contribution of donor-DNA (mean 26.6%) in buccal sam-
ples in 61 out of 68 evaluable patients. In addition, 32% of the sam-
ples were positive for microsatellite instability. The extent of
donor-DNA was significantly correlated with the occurrence of
genomic alterations (p\0.05). The age of the patient and a female-
to-male transplantation were significantly correlated with
microsatellite instability. There was a trend for increasing risk of
microsatellite instability for patients who experienced severe
graft-versus-host disease. During follow up secondary malignancy
was diagnosed in 5 patients (14%) who exhibited microsatellite in-
stability but only in 1 (3%) with no instability. In an in vitro model,
we demonstrated that apoptotic lymphocytes may not only induce
genomic alterations but also transfer DNA in co-cultured epithelial
cells, resulting in the creation of hybrid chromosomes. Our results
indicate that continuous charge of the transplant recipient with ap-
optotic donor-DNA and its illegitimate integration into host epi-
thelium may come in light as epithelial cells with donor-derived
genome or instability events and may provide a new model for elu-
cidating protean clinical manifestations after allo-HCT, such as
secondary malignancy.88
ALDHBR HEMATOPOIETIC PROGENITORS PROMOTE SHORT-TERM EN-
GRAFTMENT IN EXPERIMENTAL MODELS FOR CORD BLOOD TRANS-
PLANTATION
Storms, R.W.1, Liu, C.1, Tracy, E.2, Gentry, T.3, Balber, A.3,
Kurtzberg, J.4 1Duke University, Durham, NC; 2Duke University, Dur-
ham, NC; 3Aldagen, Inc., Durham, NC; 4Duke University, Durham,
NC
We previously developed methods to purify human hematopoi-
etic progenitors based on their high expression of aldehyde dehydro-
genase (ALDHbr cells), which enrich both short- and long-term
SCID-repopulating cells. One clinical trial now suggests that aug-
menting a conventional cord blood transplant (CBT) with ALDHbr
cells accelerates both neutrophil and platelet engraftment. We now
describe two experimental models for this clinical regimen, per-
formed in different strains of NOD/SCID mice. Each study in-
cluded three cohorts: (1) mice transplanted with 4,000 purified
ALDHbr cells; (2) mice transplanted with total CB at a dose that
contained 4,000 ALDHbr cells; and, (3) mice that first received the
same dose of unmanipulated CB and, after 4 hours, the ALDHbr
cells.
In NOD/SCID-IL2Rgnull (NSg) mice, human ALDHbr cells ex-
hibited strong chimerism including bone marrow CD33+CD15+
neutrophils and circulating CD41+ platelets, by 4 weeks post-trans-
plant. Unmanipulated CB also engrafted the bone marrow of NSg
mice, but .95% of the cells were CD3+ T cells. Myeloid engraft-
ment was low to undetectable. When CB grafts were augmented
with ALDHbr cells, bone marrow chimerism increased .2-fold rel-
ative to mice that received CB alone (P5 0.006). However, like
mice that received CB alone, the human cells within the bone mar-
row were mainly T cells; myeloid engraftment remained low to
undetectable.
